What new minimally invasive procedures are emerging for benign prostatic hyperplasia (BPH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Emerging Minimally Invasive Procedures for BPH

The newest minimally invasive procedures for BPH include water vapor thermal therapy (Rezūm), prostatic urethral lift (UroLift), and temporary implanted nitinol devices (iTind), with emerging technologies such as Aquablation, transperineal laser ablation, and novel stent-based systems (Zenflow Spring, Butterfly, ProVee) showing promise for office-based treatment. 1, 2

Currently Available Office-Based Procedures

The 2023 AUA Guideline Amendment formally recognizes several minimally invasive surgical therapies (MISTs) that represent a paradigm shift between medical management and traditional TURP 2:

Water Vapor Thermal Therapy (Rezūm)

  • Mechanism: Delivers thermal energy via water vapor to ablate prostatic tissue
  • Key advantages: Preserves sexual and ejaculatory function, can be performed in office setting
  • Evidence: Provides rapid and lasting improvement in LUTS and quality of life 3, 4
  • Consideration: Higher retreatment rates compared to TURP, but significantly better sexual function preservation

Prostatic Urethral Lift (UroLift)

  • Updated 2020 AUA guidance: May be offered for prostates <80g without obstructive middle lobe 5
  • Important change: Previous language about "less significant symptom reduction compared to TURP" was removed from guidelines, reflecting improved evidence from the L.I.F.T study 5
  • Optimal candidates: Men prioritizing ejaculatory preservation and rapid recovery

Temporary Implanted Prostatic Devices (TIPD/iTind)

  • Newest addition: Added to 2023 AUA guidelines as a formal statement 2
  • Mechanism: Mechanical expansion device temporarily implanted to reshape prostatic urethra
  • Profile: Minimal adverse events, outpatient procedure, preserves sexual function 3

Emerging Technologies on the Horizon

Based on the most recent 2025 review 1 and 2026 state-of-the-art analysis 6, several novel approaches are advancing:

Energy-Based Innovations

  • Aquablation (AQUABEAM System): Robotic waterjet treatment with image-guided precision 1, 7
  • Transperineal Laser Ablation (TPLA): Minimizes urethral trauma by accessing prostate through perineum 6, 8
  • Transurethral Ultrasound Ablation & High-Intensity Focused Ultrasound: Non-incisional thermal ablation 8
  • Histotripsy (Vortx Rx System): Mechanical tissue disruption using focused ultrasound 7

Novel Stent-Based First-Line Interventional Therapies (FITs)

These represent the cutting edge for temporary or long-term decompression with minimal procedural requirements 6:

  • Zenflow Spring System: Temporary decompression device
  • Butterfly Prostatic Retraction Device: Mechanical retraction without tissue destruction
  • ProVee Urethral Expander System: Expandable urethral support
  • Urocross Expander System: Alternative mechanical expansion approach
  • FloStent: Stent-based decompression

Balloon Dilation Technologies

  • Optilume BPH Catheter System: Drug-coated balloon dilation to prevent restenosis 6, 8
  • Transurethral Columnar Balloon Dilation: Mechanical expansion approach 8
  • CoreTherm: Thermal balloon technology 6

Clinical Decision Framework

When considering these newer procedures, prioritize based on:

  1. Prostate anatomy:

    • UroLift requires <80g prostate without middle lobe 5
    • Rezūm effective across various sizes
    • TIPD suitable for smaller prostates

  2. Patient priorities:

    • Sexual function preservation: All MISTs superior to TURP for ejaculatory preservation 3, 4
    • Rapid recovery: Office-based procedures allow same-day discharge 4
    • Symptom improvement magnitude: Traditional surgery (TURP, HoLEP) still provides greater IPSS reduction 3

  3. Durability expectations:

    • MISTs show 1-5 year durability depending on modality 6
    • Higher retreatment rates than conventional surgery 3
    • Trade-off between invasiveness and long-term efficacy

Important Caveats

Prostate Artery Embolization (PAE) remains controversial—the 2020 AUA guideline explicitly states it "is not supported by current data and trial designs, and benefit over risk remains unclear; therefore, PAE is not recommended outside the context of clinical trials" 5. This reflects insufficient evidence for routine clinical use despite commercial availability.

Legacy technologies like TUNA and TUMT were removed from the 2023 AUA guideline statements (relegated to background only) 2, suggesting these are being phased out in favor of newer MISTs with better evidence profiles.

The 2023 EAU guidelines 9 emphasize that endoscopic enucleation techniques (HoLEP, bipolar enucleation) remain superior to resection techniques for larger prostates, with comparable outcomes to open prostatectomy but faster recovery 9. These established laser procedures continue to represent the gold standard for definitive surgical management when office-based MISTs are insufficient.

References

3
Research

[Office-based therapies for benign prostatic hyperplasia : Update on new minimally invasive surgery therapies].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2021

4
Research

Office-Based Procedures for BPH.

Current urology reports, 2021

Related Questions

What minimally invasive surgical procedures are available for an adult male patient with symptomatic benign prostatic hyperplasia who has failed medical therapy?
Does tomato consumption help with benign prostatic hyperplasia?
What is the appropriate management for a 70‑year‑old male with benign prostatic hyperplasia who presents with cloudy, foul‑smelling urine, urinary frequency, urgency, and fever?
What is the recommended treatment for symptomatic benign prostatic hyperplasia in an adult male?
Can masturbation prevent benign prostatic hyperplasia?
What is the appropriate treatment for burning mouth syndrome?
When is the Spanner® temporary prostatic stent indicated for benign prostatic hyperplasia, and what are the placement criteria, contraindications, and follow‑up recommendations?
What is the immediate management of a patient presenting with tachycardia and mediastinal shift on chest imaging?
What new drugs are upcoming for the treatment of benign prostatic hyperplasia?
In patients with malignant pleural effusion, when is administration of human albumin indicated?
Is it possible to have a combination of primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.